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OBSERVATIONS ON THE USE OF THE GNRH VACCINE GONACONTM  
IN MALE WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS) 
 
G. KILLIAN, Almquist Research Center, The Pennsylvania State University, University Park, 
PA, USA 
D. WAGNER, Deer Research Center, The Pennsylvania State University, University Park, PA, 
USA 
L. MILLER, USDA, APHIS, Wildlife Services, National Wildlife Research Center, Fort Collins, 
CO, USA  
 
Abstract:  Observations made over an 11 year period during the development and evaluation of 
the GnRH vaccine GonaConTM use in male white-tailed deer (Odocoileus virginianus) are 
summarized. Sexually mature bucks at the Penn State Deer Research Center were administered a 
single immunization of GonaConTM in July. Some males were also given a second boost 
immunization in September. Compared to similar aged controls, testicular size for treated males 
was considerably reduced in the first and subsequent years of study, as were testosterone 
concentrations and sexual libido. During the first year, antler development was relatively normal 
leading to antler hardening, although shedding occurred early. However, in subsequent years, 
antlers were generally smaller, remained in velvet throughout the winter, and froze and then 
broke off. Most males given the single immunization returned to breeding condition in 2-3 years, 
although they tended to be smaller than similar-aged males. Males given the two immunizations 
tended to remain in a treated state longer. Treated males that died during the study had a higher 
incidence of pulmonary disease than non-treated males. We conclude that while GonaConTM 
reduces the reproductive capacity of male white-tailed deer, the negative effects on health and 
antler development make it impractical for field application with bucks. 
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INTRODUCTION 
Gonadotropin releasing hormone 
(GnRH) vaccines are intended to stimulate 
an animal’s immune system to produce 
antibodies against GnRH, a small peptide 
protein produced by the hypothalamus of the 
brain. Because GnRH is responsible for 
stimulating anterior pituitary gland 
hormones which regulate gamete and 
hormone production by the gonads of both 
males and females, inactivation of GnRH by 
an antibody results in an “immunological” 
castration. Most published studies 
evaluating anti-fertility effects of a GnRH 
vaccine in mammals have been directed at 
livestock and pets (Adams and Adams 1992, 
Ladd et al. 1994, Meloen et al. 1994, Rabb 
et al. 1990, Robertson 1982, Thompson, 
2000). These have largely been short-term 
studies to seek alternatives to castration or in 
the case of pigs, as a means to reduce boar 
taint (Dunshea et al. 2001). Recently 
however, we have shown that the GnRH 
vaccine is effective in impairing 
reproductive parameters of feral (Killian et 
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al. 2003) and domestic boars (Miller et al. 
2003). 
The effectiveness of a GnRH vaccine 
is dependent on having a sustainable 
antibody titer which is sufficient to 
inactivate endogenous GnRH.  Small 
peptides such as GnRH do not provide 
adequate stimulus to the immune system to 
mount a response. Peptides are typically 
coupled to a larger protein which the 
immune system will recognize as foreign 
and serve as a stimulus for the immune 
response. One large protein commonly used 
in coupling to stimulate an immune response 
to a small peptide is Keyhole Limpet 
Hemocyanin (KLH). KLH is a highly 
glycosilated mollusk protein which is quite 
immunogenic in mammals.  The nature of 
the coupling protein and the 
vehicle/adjuvant used to inject the vaccine 
are the primary determinants of the 
magnitude of the antibody titer produced 
and its duration. These are important points 
to consider during the development of a 
long-acting contraceptive vaccine. 
The development of a contraceptive 
vaccine for wildlife involves an evolving 
process by which results of previous 
experiments shape the next studies in the 
series. Pen studies with white-tailed deer are 
expensive, given the initial cost of animals 
and maintenance expenses. With limited 
resources and budgets, this by necessity 
limits the sample size for a given study. 
Nevertheless, pen studies enable detailed 
sampling at multiple time points on the same 
animal which generally provides a fuller 
understanding of the animal’s response to a 
treatment than is possible in field work. 
Our work in this area was initiated in 
1994 and subsequently led to the 
development and testing of the GnRH 
vaccine, GonaConTM. The primary focus of 
the effort has been to evaluate the vaccine in 
female deer. Does were observed for 
reproductive behavior, animal health and 
interactions among individuals. Hormonal 
status, antibody titers, and other blood 
parameters also were monitered and body 
measurements taken from all subjects. Early 
pregnancy was determined by ultrasound 
and later confirmed with fawning rates.  An 
86% reduction in fawning was achieved 
during active immunization and a 74% 
reduction over 5 years (Miller et al. 2000a, 
Killian and Miller 2001).  Does given the 
GnRH vaccine had reduced progesterone 
concentrations, reduced estrous behavior 
and evidence of both ovulation failure and 
failure to maintain pregnancy following 
conception.  Infertility lasted up to 2 years 
without a booster injection. During the past 
11 years we also have evaluated the effects 
of the GnRH vaccine in bucks. Although 
these studies did not directly evaluate the 
effect of the vaccine on individual male 
fertility, indirect indicators of their 
reproductive status in rut such as plasma 
testosterone, testis size, body mass and 
antler development were monitored. We 
now report the results of these studies with 
bucks using this GnRH vaccine. 
 
MATERIALS AND METHODS 
The study was conducted at the Deer 
Research Center at the Pennsylvania State 
University over an eleven year period from 
1994-2004. All animal procedures were 
approved by the Institutional Animal Care 
and Use Committee of Penn State. Bucks 
were chemically restrained during handling 
with 2.2-4.4mg/kg of xylazine administered 
IM in the rump. Anesthesia was reversed 
with Tolazine at 4mg/kg given IV or IM. 
The GnRH vaccine, consisting of the GnRH 
peptide conjugated to KLH was 
administered as a single shot, or a single 
shot follow by a second immunization. 
During the development stage of the 
vaccine, the GnRH-KLH component was 
administered in a 1 ml dose containing 
Freund’s complete adjuvant and mineral oil 
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(Miller et al. 2000a). A second 
immunization was typically given 4-6 weeks 
later using Freund’s incomplete adjuvant. 
Preliminary studies evaluated several doses 
of the vaccine and compared subcutaneous 
versus intra-dermal versus intra-muscular. 
From these studies we adopted a standard 
protocol dose that utilized 850-1000ug of 
GnRH-KLH, injected IM in the rump. The 
latter protocol was used in the studies 
reported. 
Although not observed in the deer 
we studied, the formation of granulomatous 
lesions caused by FCA at the injection site is 
not uncommon in many species vaccinated 
with Freund’s. These observations have 
caused the USDA to raise the classification 
of use of FCA in experimental animals from 
a Category C to Category D, among their 
definitions of painful procedures.  Therefore 
we developed an alternative adjuvant called 
AdjuVac, which was used in the studies 
reported.  When AdjuVac was used with 
GonaConTM in place of FCA, sustained 
antibody titers were observed comparable to 
FCA, without any evidence of a tissue 
reaction. 
Blood samples were collected 5-6 
times from July through February from the 
jugular vein. After clotting, the serum was 
harvested by centrifugation and stored 
frozen at -20C until assay. Serum was used 
to determine antibody titers to GnRH and 
concentration of testosterone using methods 
described elsewhere (Levy et al. 2004). 
During blood sampling, testis length and 
width were determined using calipers, and 
body condition and antler development was 
noted. If a buck was euthanized during the 
study, the testes and epididymides were 
removed and prepared for histological 
evaluation. 
During the 11 year period of study 
we developed the general impression that 
bucks given the GnRH vaccine were less 
healthy than non-treated males in the Penn 
State deer herd. To explore this notion 
further, a retrospective analysis was 
conducted on the causes of death of 
deceased animals determined by veterinary 
pathologists at the Pennsylvania State 
Animal Diagnostic Lab located on the Penn 
State campus. This study was limited to 
comparing the causes of death between the 
groups rather than the incidence of death for 
the populations. 
 
RESULTS AND DISCUSSION  
Antibody titers for most treated bucks 
reached values of 1:128,000 or greater by 
10-12 weeks post vaccination, which 
coincided with rut. Bucks with titers less 
than that in general showed less of an effect 
of the vaccine. Bucks receiving the boost 
vaccination sustained the 128,000 titer 
longer, especially into the second breeding 
season. Based on our experience with does 
and bucks given the GnRH vaccine in earlier 
studies (Miller et al. 2000a), the ability to 
obtain a high titer that is sustainable is key 
to the vaccine’s ability to inhibit 
reproduction.   
The most apparent effect of GnRH 
vaccine use in bucks was the alteration of 
antler development. During the first year 
antlers of treated males typically hardened 
and the males rubbed out of velvet. 
However, antlers of GnRH vaccine treated 
males were shed approximately 4-6 weeks 
earlier than non-treated controls. If antibody 
titers were adequate to suppress testosterone 
production by the testis during the second 
year following immunization, the antlers 
grew but failed to harden. Considering the 
normal antler growth cycle of deer (Figure 
1) it is evident that as testicular testosterone 
increases in mid summer, there is a 
corresponding increase in antler growth. The 
rise in testosterone is also associated with 
antler hardening and shedding of velvet that 
occurs prior to rut. During first breeding 
season following GnRH vaccine treatment 
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in July, there is a time delay before an effect 
is seen. Antlers typically develop and 
harden, although they are shed early. This is 
a result of the lag time necessary for the 
immune system to develop antibody titers 
sufficient to complex with most endogenous 
GnRH and the subsequent “trickle down 
effect” that eventually removes the stimulus 
for testicular hormone secretion. During the 
first year, testosterone levels are apparently 
adequate to sustain development through 
hardening, but as the antibody titers rise 
there is a drop in testosterone and antlers are 
shed prematurely. If antibody titers are 
sustained into the second year following 
vaccination, the seasonal changes associated 
with breeding are prevented because GnRH 
secretion is compromised. Consequently, 
growth and hardening of antlers facilitated 
by testosterone do not occur, and the antlers 
tend to be smaller and remain in velvet 
throughout the season.  
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Figure 1.  Serum testosterone during the normal antler growth cycle of white-tailed deer.  From 
March through early summer, the primary source of testosterone is the adrenal glands. From mid 
summer through February, the primary source of testosterone is the testis. 
 
Another notable effect of the GnRH 
vaccine on males was their failure to 
develop the muscular appearance typical of 
mature bucks in rut, analogous to a weight 
lifter on steroids (Figure 2). Removal of 
testosterone in GnRH-treated males leaves 
them with the body form of a female with 
antlers. These males show little or no 
interest in estrus does that are penned with 
them or in adjacent pens. Infrequently, 
GnRH-treated males may attempt to mount a 
doe in heat in the absence of control males, 
but the mount is not complete. Although we 
did not test fertility of the GnRH males in a 
breeding trial per se, these observations 
suggest that GnRH treated males would not 
reproduce successfully. 
The effects seen in GnRH-treated 
males on antler development, behavior and 
body mass are the direct consequence of a 
reduction of serum testosterone, which 
modulates these characteristics. For treated 
bucks in our study, there was a significant 
drop in testosterone compared to non-treated 
controls (Figure. 3). This drop in 
testosterone corresponded to histological 
changes in the testis which resembled the 
testis of males during the non-breeding 
season. In the treated males, the Leydig cells 
which produce testosterone appear inactive, 
and the seminiferous tubules are regressed 
and do not contain mature sperm. These 
observations support the conclusion that 
these males were infertile. 
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Figure 2. A comparison of body mass of males in the breeding season a GnRH vaccine treated male 
(left) and a control male of similar age. 
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Figure 3. Average plasma testosterone concentrations (n=5 males per group) during the breeding 
season for control males and males vaccinated with the GnRH vaccine in July. 
 
In practice, the use of any 
contraceptive approach with wildlife should 
be effective for multiple years, since 
opportunities to retreat the same animal will 
be unlikely. Contraceptive vaccines using 
porcine zona pellucida (PZP) as the 
immunogen have been reported to be 
effective in does for 1-2 years (Turner et al. 
1992; Miller et al, 2000b). In ongoing 
studies in our deer herd testing the effect of 
the PZP vaccine SpayVac on does, we have 
observed 80% contraceptive efficacy after 4 
years. Although we have not conducted 
extensive long-term studies with the GnRH 
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vaccine in bucks, there is evidence that the 
inhibitory effects of the vaccine are present 
for multiple years based on testicular size 
(Table 1) and plasma testosterone 
concentration (Table 2) during rut.  
Compared to controls, males receiving the 
single or two shot regimen on average had 
reduced testicular size and plasma 
testosterone for at least three breeding 
seasons. In the study with the single shot 
vaccine where data were collected in the 
fourth year post vaccination, there was 
evidence that testicular function was being 
restored.  
 
Table 1. Average scrotal testis length in mm 
for (n) bucks treated with a single vaccination 
of GnRH vaccine (GnRH-1X) or a single 
vaccination followed by a boost (GnRH-2X) 
compared to untreated control males. 
Treatment Year 1 
Year 
2 
Year 
3 
Year 
4 
Controls 74(3) - - - 
GnRH-1X 44(5) 38(5) 58(3) 65(2) 
GnRH-2X 40(5) 46(3) 39(3) - 
 
Table 2.  Average ng of serum testosterone 
for (n) bucks treated with a single vaccination 
of GnRH vaccine (GnRH-1X) or a single 
vaccination followed by a boost (GnRH-2X) 
compared to untreated control males. 
Treatment Year 1 Year 2 
Year 
3 Year 4
Control 603(3) - - - 
GnRH-1X 6(5) 28(5) 10(3) 175(2) 
GnRH-2X 30(5) 23(3) 50(3)   
 
Data on testicular function must be 
interpreted somewhat cautiously however, 
when predicting male fertility. It is possible 
that while average testicular size and plasma 
testosterone were reduced, some level of 
sperm production may have occurred in 
some of the bucks. Unfortunately, we did 
not examine histology of the testes of all of 
the treated males, but based on studies we 
have conducted with feral swine (Killian et. 
al. 2003, Killian et al, unpublished), it is 
certainly possible that some sperm 
production could occur. However, the 
reduced testicular function of GnRH treated 
bucks may not be adequate to assume 
successful reproductive function. Moreover, 
the failure of antlers to harden, the lack of 
interest in estrus does and the female like 
body mass suggest that GnRH vaccine-
treated males would not be reproductively 
active. 
Our ability to closely monitor 
individual males during the course of these 
studies led us to believe that GnRH-treated 
males may be less healthy than non-treated 
males in the Penn State herd. To explore this 
possibility, necropsy reports were examined, 
if available, to assess the causes of death for 
GnRH-treated and untreated males that died 
during the 11 years of study. Causes of 
death included bone fractures and associated 
infections, enterocolitis and pulmonary 
diseases including pneumonia, 
pleuropneumonia, pulmonary abscession, 
and bronchopneumonia. For both the control 
and GnRH-treated bucks, pulmonary 
diseases were the single greatest cause of 
death (Table 3). This agrees with a 
published study indicating that in 
Pennsylvania captive white-tailed deer, 
pulmonary disease was the most common 
cause of death (Hattel et al. 2004). For our 
study, however, the relative incidence of 
death resulting from pulmonary disease in 
the treated males was significantly greater 
than that for control bucks. We can only 
speculate on the reason for this observation. 
Microbes associated with pneumonia appear 
to be endemic in captive deer herds and 
GnRH-treated bucks appear to be less 
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resistant to infections caused by these 
microbes.  
 
Table 3. Causes of Mortality for Bucks at 
PSU Deer Research Center 1994-2004. 
Pulmonary diseases included pneumonia, 
plueropneumonia, pulmonary abscession, and 
bronchopneumonia. Other causes included 
enterocolitis and bone fractures and 
associated infections as the primary causes of 
mortality. 
  Controls    n=22 
GnRH-
treated 
      
n=13 
Pulmonary 
 Disease 41% 62%** 
Other 59% 38% 
**Significant p <.05 by Chi square. 
 
CONCLUSIONS 
We have demonstrated that both 
single and two injection protocols of 
GonaConTM were effective in altering 
reproductive function of male white-tailed 
deer for multiple years. Plasma testosterone, 
testis size, breeding behavior and body mass 
were all reduced in GnRH vaccine treated 
males compared to non-treated males. In 
addition, antler development was reduced, 
antlers failed to harden and mortality due to 
pulmonary disease was greater in treated 
males. Although GonaConTM was effective 
in impairing reproductive function, given the 
latter considerations we do not recommend 
its use for controlling fertility of bucks.  
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